Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference

Saturday, March 1, 2008 General News J E 4
CINCINNATI, Feb. 29 Kendle (Nasdaq: KNDL), aleading, global full-service clinical research organization, today announcedthat Vice President and Chief Marketing Officer Simon Higginbotham willparticipate in the 29th Annual Raymond James Institutional InvestorsConference. The conference will be held at the Hyatt Regency Grand Cypress inOrlando, March 2-5, 2008. Kendle's presentation is scheduled for Wednesday,March 5 at 1:40 p.m. Eastern Time.

(Logo: )

The public is invited to listen to a live webcast of Kendle's presentationat (click on the link provided in the Investor Eventssection) or at An archived version canbe accessed following Kendle's presentation and will be available throughApril 4. Slides accompanying the presentation will be available by 9 a.m.Eastern Time on March 5 at in the Investor Relationssection.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leadingglobal clinical research organizations. We deliver innovative and robustclinical development solutions -- from first-in-human studies through marketlaunch and surveillance -- to help the world's biopharmaceutical companiesmaximize product life cycles and grow market share.

Our global clinical development business is focused on five regions --North America, Europe, Asia/Pacific, Latin America and Africa -- to meetcustomer needs. We have conducted clinical trials and provided regulatory andpharmacovigilance services in more than 80 countries. Kendle was named "TopCRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigativesites and "Best CRO" for 2007 and 2006 by leading global pharmaceuticalpublication Scrip.

Additional information and investor kits are available upon request fromKendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from theCompany's Web site at

SOURCE Kendle International Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Vallon Holdings, LLC Launches New Subsidiary Focus...
Dialysis Corporation of America Announces Fiscal Y...